[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
1. Hsu TR, Wong TT, Chang FC, Ho DM, Tang RB, Thien PF, Chang KP: Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children. Childs Nerv Syst; 2008 Dec;24(12):1457-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Though the pathology of optic pathway tumor is mostly pilocytic astrocytoma, the benign tumor behaves like malignant tumor because total resection is not feasible.
  • Adjuvant chemotherapy might be a reasonable strategy for management of these low grade tumors which keep growing.
  • The pathology showed pilocytic astrocytomas in 11 patients, astrocytoma in one patient, and anaplastic astrocytomas in two patients.
  • The toxicity of the cisplatin-based chemotherapy showed mild bone marrow suppression in 13 patients (81.3%), infection in nine patients (56.3%), gastrointestinal discomfort in seven patients (43.8%), renal insufficiency in two patient (12.5%), cerebral salt wasting syndrome with hyponatremia in one patient (6.25%) and high pitch hearing loss in two patients (12.5%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Optic Nerve Neoplasms / drug therapy
  • [MeSH-minor] Bone Marrow Diseases / chemically induced. Child. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gastrointestinal Diseases / chemically induced. Humans. Infection / chemically induced. Magnetic Resonance Imaging. Male. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1961 Nov;49:322-31 [13923365.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1114-8; discussion 1118-9 [8727140.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):32-5 [8315466.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 May;25(5):372-8 [12759623.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):51-5 [8455063.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1467-71 [7357527.001]
  • [Cites] Pediatr Neurosurg. 1993 Jul-Aug;19(4):186-95 [8329303.001]
  • [Cites] Br J Ophthalmol. 1969 Dec;53(12):793-8 [5386369.001]
  • [Cites] J Neurosurg. 1978 Jan;48(1):34-41 [412924.001]
  • [Cites] Neuro Oncol. 2000 Oct;2(4):213-20 [11265230.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):215-25 [8420869.001]
  • [Cites] Ann Neurol. 1999 Mar;45(3):393-6 [10072056.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Jun;11(6):1067-79 [3997589.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4209-16 [12377964.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):850-6 [8487049.001]
  • [Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]
  • [Cites] Acta Paediatr. 1993 Mar;82(3):327-8 [8495098.001]
  • [Cites] Br J Ophthalmol. 1986 Mar;70(3):179-82 [3082351.001]
  • [Cites] Pediatr Neurol. 2003 Apr;28(4):262-70 [12849878.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):661-7 [2213155.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4572-8 [14673044.001]
  • [Cites] Surv Ophthalmol. 1994 Mar-Apr;38(5):427-52 [8009427.001]
  • [Cites] Neurol Clin. 1991 Feb;9(1):163-77 [2011108.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):116-20 [12672283.001]
  • [Cites] Neurol Clin. 1991 May;9(2):467-77 [1944110.001]
  • [Cites] Arch Dis Child. 1997 Mar;76(3):259-63 [9135269.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):704-10 [11597812.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2156-67 [16220552.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1051-9 [7842408.001]
  • [Cites] J Neurosurg. 1988 Jan;68(1):85-98 [3275755.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:143-6 [15662798.001]
  • [Cites] Oncology (Williston Park). 1989 Sep;3(9):23-30; discussion 34, 37-8 [2518324.001]
  • [Cites] Neurology. 1986 Sep;36(9):1173-8 [3748382.001]
  • (PMID = 18769928.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Debinski W: Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Invest; 2002;20(5-6):801-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local treatment of brain tumors with targeted chimera cytotoxic proteins.
  • High-grade astrocytomas (HGA) are the most prevalent brain tumors that represent a unique pharmaceutical challenge.
  • Their cerebral localization and characteristic features of tumor progression primarily dictate this challenge.
  • Targeted chimera conjugate/fusion cytotoxic proteins have become the newest class of investigative drug candidates for the treatment of HGA due to their inherent properties that are compatible with drug deliveries to brain tumors.
  • This immunotoxin belongs to the first group of immunotoxins that started to live up to early expectations.
  • [MeSH-major] Astrocytoma / therapy. Bacterial Toxins / therapeutic use. Brain Neoplasms / therapy. Immunotoxins / therapeutic use
  • [MeSH-minor] Drug Delivery Systems. Humans. Ligands. Proteins. Receptors, Transferrin / drug effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12197239.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA74145
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Toxins; 0 / Immunotoxins; 0 / Ligands; 0 / Proteins; 0 / Receptors, Transferrin
  • [Number-of-references] 76
  •  go-up   go-down


3. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol; 2003 Dec;14(12):1715-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
  • BACKGROUND: The aim of this study was to assess the efficacy of temozolomide in patients with World Health Organisation (WHO) grade II gliomas treated with surgery alone using imaging and clinical criteria.
  • PATIENTS AND METHODS: Thirty patients with histologically verified WHO grade II gliomas (17 astrocytoma, 11 oligodendroglioma, two mixed oligoastrocytoma) following surgery 2-104 months (median 23 months) after initial diagnosis received temozolomide 200 mg/m(2)/day for 5 days, on a 28-day cycle, for a maximum of 12 cycles or until tumour progression.
  • Tumour size was measured as the high signal intensity area on fluid attenuated inversion recovery sequences.
  • Responses were assessed using change in the product of two perpendicular diameters as complete response (CR), partial response (PR), minimal response (MR), stable disease (SD) and progressive disease (PD).
  • Three patients had a PR, 14 MR, 11 SD and one PD.
  • Six patients had transient grade III/IV haematological toxicity (11 episodes; 3.5%).
  • CONCLUSIONS: Temozolomide has single-agent activity in patients with WHO grade II cerebral glioma, with modest improvement in quality of life and improvement in epilepsy control.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2003 Dec;14(12):1695-6 [14630671.001]
  • (PMID = 14630674.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


Advertisement
4. Rauscher A, Sedlacik J, Fitzek C, Walter B, Hochstetter A, Kalff R, Kaiser WA, Reichenbach JR: High resolution susceptibility weighted MR-imaging of brain tumors during the application of a gaseous agent. Rofo; 2005 Aug;177(8):1065-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High resolution susceptibility weighted MR-imaging of brain tumors during the application of a gaseous agent.
  • PURPOSE: To employ a high resolution blood oxygenation level dependent (BOLD) method called susceptibility weighted imaging (SWI) together with the breathing of carbogen to investigate the response of cerebral tumors to this breathing gas and to assess tumor anatomy at high resolution.
  • METHODS: Five patients with cerebral tumors (four glioblastoma multiforme, one astrocytoma [WHO grade II]) were studied using a susceptibility weighted 3D gradient echo, first order velocity compensated sequence (TE = 45 ms, TR = 67 ms, alpha = 25 degrees , FOV = 256 x 192 x 64 mm(3), typical matrix = 512 x 192 x 64), on a 1.5 T MR scanner while they were breathing air and carbogen.
  • The astrocytoma displayed a signal decrease during carbogen breathing (- 4.1 +/- 0.1 % to - 6.8 +/- 0.3 % in peritumoral areas that correspond to hyperintense regions on T (2)-weighted images, and - 3.1 +/- 0.1 % in the tumor-center).
  • CONCLUSIONS: SWI provides high resolution images of cerebral anatomy and venous vascularization.
  • [MeSH-minor] Adult. Astrocytoma / diagnosis. Contrast Media. Female. Glioblastoma / diagnosis. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16021537.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 142M471B3J / Carbon Dioxide; 8063-77-2 / carbogen; S88TT14065 / Oxygen
  •  go-up   go-down


5. Ozkan M, Altinbas M, Er O, Kaplan B, Coskun HS, Karahacioglu E, Menku A, Cihan Y, Kontas O, Akdemir H: Post-operative sequential chemo-radiotherapy in high-grade cerebral gliomas with fotemustine. J Chemother; 2004 Jun;16(3):298-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-operative sequential chemo-radiotherapy in high-grade cerebral gliomas with fotemustine.
  • High-grade gliomas are the most common primary brain tumors in adults.
  • Twenty-seven patients with histopathologically proven anaplastic astrocytoma and glioblastoma multiforme were enrolled in this study from November 1998 to August 2002.
  • This trial demonstrates that postoperative radiotherapy and sequential fotemustine therapy is feasible, well tolerated, and may prolong survival in patients with newly diagnosed high-grade gliomas.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Fotemustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15330329.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; GQ7JL9P5I2 / fotemustine
  •  go-up   go-down


6. Li JY, Wang H, May S, Song X, Fueyo J, Fuller GN, Wang H: Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. J Neurooncol; 2008 May;88(1):11-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas.
  • In this study, we used an immunohistochemical approach to examine the activation status of JNK of 226 gliomas in a high-density tissue microarray comprising all WHO codified WHO diffuse glioma subtypes and grades.
  • The results were correlated with grade and EGFR expression status.
  • Constitutively activated JNK (pJNK) was detected in 90.5%, 62.9% and 17.5% of WHO grade IV, III and II gliomas, respectively (p < 0.001).
  • pJNK expression was not detected in the astrocytes or oligodendrocytes of any of 10 normal cerebral and cerebellar brain tissue samples.
  • [MeSH-minor] Astrocytoma / drug therapy. Astrocytoma / pathology. Blotting, Western. Cells, Cultured. Enzyme Activation / physiology. Glioblastoma / drug therapy. Glioblastoma / pathology. Gliosarcoma / drug therapy. Gliosarcoma / pathology. Humans. Immunohistochemistry. Oligodendroglioma / drug therapy. Oligodendroglioma / pathology


7. Samnick S, Hellwig D, Bader JB, Romeike BF, Moringlane JR, Feiden W, Kirsch CM: Initial evaluation of the feasibility of single photon emission tomography with p-[123 I]iodo-L-phenylalanine for routine brain tumour imaging. Nucl Med Commun; 2002 Feb;23(2):121-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour lesions were clearly demonstrated by IPA SPET at 30 min, 1h and 4.5h post-injection, even in patients with low grade gliomas.
  • In patients with glioblastoma, excellent visualization of the tumour was possible even at 7h p.i., indicative of the high retention of the radiopharmaceutical in cerebral gliomas.
  • Analysis of the radioactivity in plasma and urine attested to the high in vivo stability of IPA.
  • This result strongly suggests that IPA is a potentially valuable brain tumour imaging agent for widespread clinical studies with SPET.
  • Its high specific tumour uptake and retention even in low grade gliomas represent a major advantage compared to presently available SPET radiopharmaceuticals.
  • [MeSH-major] Astrocytoma / radionuclide imaging. Brain Neoplasms / radionuclide imaging. Glioblastoma / radionuclide imaging. Phenylalanine / analogs & derivatives. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adult. Aged. Animals. Feasibility Studies. Female. Fluorodeoxyglucose F18. Humans. Iodine Radioisotopes / pharmacokinetics. Magnetic Resonance Imaging. Male. Middle Aged. Radiopharmaceuticals. Rats. Rats, Sprague-Dawley. Retrospective Studies. Whole-Body Counting

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11891465.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 47E5O17Y3R / Phenylalanine; J882Z73MPL / 4-iodophenylalanine
  •  go-up   go-down


8. Choi JW, Lee MM, Kim IA, Kim JH, Choe G, Kim CY: The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study. J Korean Neurosurg Soc; 2008 Oct;44(4):222-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study.
  • OBJECTIVE: Malignant gliomas are the most common primary cerebral neoplasms in adults.
  • METHODS: Thirty-two patients over the age of 17 years with newly diagnosed and histologically confirmed high-grade gliomas (HGG), from June 2004 to August 2007 were the subjects of this study.
  • Pathologically, glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, and gliomatosis cerebri had been diagnosed in eighteen, eight, four, and two patients, respectively.
  • There was no mortality caused by drug toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2192-7 [18445844.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1371-80 [10780513.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1111-39, x [17964028.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4127-36 [17827463.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Nov;60(2):99-111 [17027279.001]
  • [Cites] Tumori. 2006 Jul-Aug;92(4):299-305 [17036520.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Cancer Radiother. 2005 Sep;9(5):322-31 [16095943.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Strahlenther Onkol. 2005 Mar;181(3):157-63 [15756519.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3851-7 [9850030.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):826-36 [2585073.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Can J Neurol Sci. 2007 Nov;34(4):402-10 [18062446.001]
  • (PMID = 19096681.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588321
  • [Keywords] NOTNLM ; Concomitant chemoradiotherapy / Glioblastoma / High-grade glioma / Temozolomide
  •  go-up   go-down


9. Clavo B, Robaina F, Morera J, Ruiz-Egea E, Pérez JL, Macías D, Caramés MA, Catalá L, Hernández MA, Günderoth M: Increase of brain tumor oxygenation during cervical spinal cord stimulation. Report of three cases. J Neurosurg; 2002 Jan;96(1 Suppl):94-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant brain tumors have been shown to decrease O2 and blood flow resulting in hypoxia and low perfusion that in turn reduce radiation sensitivity and access by chemotherapeutic agents.
  • In the present study the authors applied the method and, with polarographic probes inserted in the tumor sites, measured the changes in tissue oxygenation and hypoxia in two separate tumor areas in three patients with high-grade astrocytomas.
  • [MeSH-major] Astrocytoma / blood supply. Brain Neoplasms / blood supply. Cell Hypoxia / physiology. Electric Stimulation Therapy. Glioblastoma / blood supply. Glioma / blood supply. Oxygen Consumption / physiology. Spinal Cord / physiopathology
  • [MeSH-minor] Adult. Aged. Cerebral Cortex / blood supply. Cerebral Cortex / radiation effects. Cerebral Cortex / surgery. Combined Modality Therapy. Electrodes, Implanted. Female. Humans. Male. Middle Aged. Polarography. Radiotherapy, Adjuvant. Regional Blood Flow / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11795721.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Qureshi AI, Suri MF, Khan J, Sharma M, Olson K, Guterman LR, Hopkins LN: Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures. J Neurooncol; 2001 Jan;51(2):151-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The results of animal studies suggest that superselective intra-arterial infusion allows the permeation of a high concentration of chemotherapeutic agents within intracranial neoplasms.
  • The infusions were performed through superselective microcatheterization of the following arteries: internal carotid (n = 39), middle cerebral (n = 61), posterior cerebral (n = 21) and anterior cerebral (n = 10).
  • The tumors were classified as glioblastoma multiforme (n = 12), metastatic tumor (n = 1), high-grade astrocytoma (n = 6), and anaplastic mixed glioma (n = 5).
  • [MeSH-major] Brain Neoplasms / drug therapy. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Glioma / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Bradykinin / analogs & derivatives. Bradykinin / therapeutic use. Carotid Arteries. Cerebral Arteries. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1994 Nov;81(5):752-8 [7931623.001]
  • [Cites] J Neurooncol. 1989 May;7(1):39-45 [2547032.001]
  • [Cites] Semin Oncol. 1994 Oct;21(5 Suppl 12):114-8 [7992063.001]
  • [Cites] Neuroradiology. 1991;33(5):432-7 [1749475.001]
  • [Cites] Cancer Treat Rep. 1981;65 Suppl 2:27-37 [7346144.001]
  • [Cites] Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):140S-145S [9322881.001]
  • [Cites] J Neurooncol. 1999 Mar;42(1):73-7 [10360481.001]
  • [Cites] J Pharm Pharmacol. 1997 Aug;49(8):777-80 [9379355.001]
  • [Cites] J Neurosurg. 1992 May;76(5):772-81 [1564540.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):235-46 [10359143.001]
  • [Cites] Arch Neurol. 1992 Jan;49(1):83-6 [1728268.001]
  • [Cites] Semin Oncol. 1995 Oct;22(5 Suppl 12):88-90 [7481869.001]
  • [Cites] Cancer Res. 1982 May;42(5):2059-62 [7199971.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):121-31 [9266448.001]
  • [Cites] Neurosurgery. 1992 Apr;30(4):512-6; discussion 516-7 [1316564.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):409-22 [10458260.001]
  • [Cites] Neoplasma. 1989;36(3):349-52 [2544815.001]
  • [Cites] Neurosurgery. 1999 Feb;44(2):270-8; discussion 278-9 [9932880.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] J Neurooncol. 1987;5(3):245-50 [3681387.001]
  • [Cites] AJNR Am J Neuroradiol. 1983 May-Jun;4(3):810-2 [6410860.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):125-33; discussion 133-4 [8805148.001]
  • (PMID = 11386412.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 159768-75-9 / RMP 7; BG3F62OND5 / Carboplatin; S8TIM42R2W / Bradykinin
  •  go-up   go-down


11. Wolff JE, Wagner S, Sindichakis M, Pietsch T, Gnekow A, Kortmann RD, Sträter R, Kuehl J: Simultaneous radiochemotherapy in pediatric patients with high-grade glioma: a phase I study. Anticancer Res; 2002 Nov-Dec;22(6B):3569-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous radiochemotherapy in pediatric patients with high-grade glioma: a phase I study.
  • PATIENTS AND METHODS: Twenty-nine children with high-grade glioma were treated from 1997-1999.
  • Tumor locations included: cerebral cortex 12, deep cerebral locations 11, cerebellum 3, spinal cord 3.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioma / drug therapy. Glioma / radiotherapy. Spinal Cord Neoplasms / drug therapy. Spinal Cord Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Astrocytoma / surgery. Child. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cohort Studies. Combined Modality Therapy / adverse effects. Dose Fractionation. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Prospective Studies

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12552957.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


12. Papadopoulos MC, Saadoun S, Woodrow CJ, Davies DC, Costa-Martins P, Moss RF, Krishna S, Bell BA: Occludin expression in microvessels of neoplastic and non-neoplastic human brain. Neuropathol Appl Neurobiol; 2001 Oct;27(5):384-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant brain tumours cause cerebral oedema because they have leaky endothelial tight junctions, which allow plasma fluid to enter the brain from the microvessel lumen.
  • The proportions of microvessels immunolabelling for occludin were >2/3 in 5/5 non-neoplastic brain tissue samples, >1/3 in 5/5 low grade (Daumas-Duport I or II) astrocytomas and <1/3 in 5/5 high grade (III or IV) astrocytomas and 6/6 metastatic adenocarcinomas.
  • Six non-neoplastic brain tissue immunoblots gave a 55-kDa occludin band, three low-grade astrocytomas gave 55-kDa and 60-kDa bands, 13 high-grade astrocytomas gave 60-kDa or no band and four adenocarcinomas did not give an occludin band.
  • Electron microscopy showed open endothelial tight junctions in 0/2 non-neoplastic human brain specimens and 2/2 high-grade astrocytomas.
  • Characterizing the molecular pathology of brain endothelial tight junctions may facilitate the design of novel drugs against cerebral oedema.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Endothelium, Vascular / metabolism. Membrane Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11679090.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / OCLN protein, human; 0 / Occludin
  •  go-up   go-down






Advertisement